Abstract
Transitioning from administration of monthly palivizumab to a single dose at discharge was associated with substantial pharmacy cost savings. With the concurrent adoption of private hospital rooms and visitor restriction policies, hospital-wide and neonatal intensive care unit healthcare-associated respiratory syncytial virus infections decreased following these changes.
Original language | English (US) |
---|---|
Pages (from-to) | 485-487 |
Number of pages | 3 |
Journal | Infection Control and Hospital Epidemiology |
Volume | 39 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2018 |
Funding
Financial support. Research reported in this publication was supported, in part, by the National Institutes of Health National Center for Advancing Translational Sciences (grant no. UL1TR001422).
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
- Epidemiology